ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2180

Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Primary Sjögren’s Syndrome

F. Atzeni1, L. Boccassini1, M.C. Signorello2, MA Carrideo2, L. Gianturco2, V. De Gennaro Colonna3, L. Drago4, M. Turiel2 and P. Sarzi-Puttini1, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2IRCCS Galeazzi Orthopedic Institute, University of Milan, Department of Health Technologies, Cardiology Unit,, Milan, Italy, 3Pharmacology Department, University of Milan, Milan, Italy, 4Laboratory Unit, IRCCS Galeazzi Orthopedic Institute, Department of Health Technologies, University of Milan, Milan, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome - Clinical

Session Type: Abstract Submissions (ACR)

Background/Purpose: Clinical and biochemical data suggest that autoimmune diseases are associated with endothelial dysfunction and increased atherosclerosis. We have previously shown that asymmetric dimethylarginine (ADMA) levels and coronary flow reserve (CFR) are impaired in patients with early rheumatoid arthritis, but it is not known whether the same is true of patients with  primary Sjögren’s syndrome (SS). We therefore investigated sub-clinical cardiovascular involvement in primary SS patients by means of ADMA and coronary flow reserve (CFR) assessments.

Methods: The study involved 15 patients who fulfilled the ACR criteria for primary SS without any documentable cardiovascular disease and 20 age- and gender-matched control subjects. Dipyridamole transthoracic stress echocardiography was used to evaluate wall motion and CFR in the distal segment of the left anterior descending coronary artery before and after dipyridamole infusion (0.86 mg/kg over six minutes). A CFR value of <2.5 was considered a sign of impaired coronary functionPlasma ADMA levels were determined using high-performance liquid chromatography. Linearity was assessed in the range of ADMA 0.1-20 μM. The mean correlation coefficient was >0.99. The ADMA limit of quantitation (LOQ) was 0.01 μM.The continuous variables were expressed as mean values and standard deviations, and the non-continuous variables as median values and interquartile ranges (IQR). The data were analysed using SAS statistical software 9.2. All tests were two-tailed, and probability (p) values of less than 0.05 were considered statistically significant.

Results: All of the patients were affected by primary SS, the majority of patients were being treated with hydroxychloroquine (HCQ) at dose of 400 mg/day, two were taking methotrexate (MTX) and four azathioprine (AZA) at a mean dose of 150 mg/day (range 50-200 mg). Only 3 patients used corticosteroids – one at a dosage of 2.5 mg and two at 5 mg/daily. All of the patients were ANA and/or RF and anti-SSB and/or anti-SSA positive.  The patients’ mean age and ejection fraction were respectively 62 ± 8 years and 65% ± 6% (not significant). Although within the normal range, their CFR was lower than that of the controls ( median 3.0, IQR  2.5 – 3.5 vs median 3.4, IQR 3.2 – 3.82, P=0.02 ), whereas their ADMA levels were significantly higher (median 0.80 mM, IQR 0.78-0.82mM vs median 0.55mM, IQR 0.49-0.59mM respectively; P <0.0001) and their E/A ratios significantly lower ( median 0.8, IQR 0.7 - 1.1 vs median 1.3, IQR 1.3, 1.2 – 1.4; P <0.0001).

Conclusion: Higher ADMA levels suggest the presence of endothelial dysfunction and sub-clinical atherosclerosis in primary SS patients, even in the case of normal CFR. Our preliminary data indicate that ADMA may be a useful marker for identifying early endothelial dysfunction in primary SS patients.


Disclosure:

F. Atzeni,
None;

L. Boccassini,
None;

M. C. Signorello,
None;

M. Carrideo,
None;

L. Gianturco,
None;

V. De Gennaro Colonna,
None;

L. Drago,
None;

M. Turiel,
None;

P. Sarzi-Puttini,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coronary-flow-reserve-and-asymmetric-dimethylarginine-levels-new-measurements-for-identifying-subclinical-atherosclerosis-in-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology